KR102077374B1 - 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물 - Google Patents

연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물 Download PDF

Info

Publication number
KR102077374B1
KR102077374B1 KR1020177009224A KR20177009224A KR102077374B1 KR 102077374 B1 KR102077374 B1 KR 102077374B1 KR 1020177009224 A KR1020177009224 A KR 1020177009224A KR 20177009224 A KR20177009224 A KR 20177009224A KR 102077374 B1 KR102077374 B1 KR 102077374B1
Authority
KR
South Korea
Prior art keywords
patients
stroke
amino acids
muscle
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177009224A
Other languages
English (en)
Korean (ko)
Other versions
KR20170057308A (ko
Inventor
파올로 루카 마리아 지오게티
Original Assignee
프로페셔날 디에테틱스 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로페셔날 디에테틱스 에스.피.에이. filed Critical 프로페셔날 디에테틱스 에스.피.에이.
Publication of KR20170057308A publication Critical patent/KR20170057308A/ko
Application granted granted Critical
Publication of KR102077374B1 publication Critical patent/KR102077374B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177009224A 2014-10-08 2015-10-07 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물 Expired - Fee Related KR102077374B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO2014A000806 2014-10-08
ITTO20140806 2014-10-08
PCT/IB2015/057662 WO2016055948A1 (en) 2014-10-08 2015-10-07 Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Publications (2)

Publication Number Publication Date
KR20170057308A KR20170057308A (ko) 2017-05-24
KR102077374B1 true KR102077374B1 (ko) 2020-02-13

Family

ID=52101507

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009224A Expired - Fee Related KR102077374B1 (ko) 2014-10-08 2015-10-07 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물

Country Status (14)

Country Link
US (1) US9707198B2 (enExample)
EP (1) EP3006027B1 (enExample)
JP (1) JP6447716B2 (enExample)
KR (1) KR102077374B1 (enExample)
AU (1) AU2015329581B2 (enExample)
CA (1) CA2958033C (enExample)
DK (1) DK3006027T3 (enExample)
ES (1) ES2651903T3 (enExample)
HU (1) HUE035699T2 (enExample)
NO (1) NO3006027T3 (enExample)
NZ (1) NZ728962A (enExample)
PL (1) PL3006027T3 (enExample)
RU (1) RU2668373C1 (enExample)
WO (1) WO2016055948A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6773269B2 (ja) * 2015-05-14 2020-10-21 プロフェッショナル ダイエテティクス エス．ピー．エー． 放射線療法および／または化学療法を受けている腫瘍患者における粘膜炎の治療における使用のためのアミノ酸を備える組成物
IT201700087376A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012117065A1 (en) * 2011-03-01 2012-09-07 Nestec S.A. Extensional viscosity to promote safe swallowing of food boluses
JP2012201625A (ja) * 2011-03-25 2012-10-22 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用栄養組成物
WO2012142678A1 (en) * 2011-04-21 2012-10-26 Fit-Bioceuticals Limited Weight loss composition
WO2014065715A1 (en) * 2012-10-24 2014-05-01 Solovyev Nikolay Vladimirovich Composition for parenteral administration, method for producing and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
IT1320783B1 (it) * 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US20030060421A1 (en) * 2001-07-19 2003-03-27 Neuron Therapeutics, Inc. Kits and compositions supporting intracranial perfusions
EP2275084A1 (en) * 2009-07-15 2011-01-19 Unilever PLC Oral care composition
RU2012105901A (ru) * 2009-07-20 2013-08-27 Нестек С.А. Способы снижения потери функционального состояния
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
WO2012133198A1 (ja) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012117065A1 (en) * 2011-03-01 2012-09-07 Nestec S.A. Extensional viscosity to promote safe swallowing of food boluses
JP2012201625A (ja) * 2011-03-25 2012-10-22 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用栄養組成物
WO2012142678A1 (en) * 2011-04-21 2012-10-26 Fit-Bioceuticals Limited Weight loss composition
WO2014065715A1 (en) * 2012-10-24 2014-05-01 Solovyev Nikolay Vladimirovich Composition for parenteral administration, method for producing and use thereof

Also Published As

Publication number Publication date
DK3006027T3 (en) 2017-12-18
NO3006027T3 (enExample) 2018-04-14
KR20170057308A (ko) 2017-05-24
NZ728962A (en) 2019-05-31
EP3006027A1 (en) 2016-04-13
CA2958033A1 (en) 2016-04-14
JP6447716B2 (ja) 2019-01-09
CA2958033C (en) 2019-07-16
ES2651903T3 (es) 2018-01-30
HUE035699T2 (en) 2018-05-28
US9707198B2 (en) 2017-07-18
EP3006027B1 (en) 2017-11-15
RU2668373C1 (ru) 2018-09-28
AU2015329581A1 (en) 2017-03-02
PL3006027T3 (pl) 2018-02-28
US20160101078A1 (en) 2016-04-14
AU2015329581B2 (en) 2019-02-07
JP2017530103A (ja) 2017-10-12
WO2016055948A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
Bo et al. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial
JP2014065740A (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
JP2003532691A (ja) 重症疾患神経障害
Aquilani et al. Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation
Lee et al. Enhancement of Lower Limb Muscle Strength and Reduction of Inflammation in the Elderly: A Randomized, Double-Blind Clinical Trial Comparing Lacticaseibacillus paracasei PS23 Probiotic with Heat-Treated Supplementation
Morita et al. Clinical evaluation of changes in biomarkers by oral intake of NMN.
KR102077374B1 (ko) 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물
Kinugasa et al. l‐Carnitine supplementation in heart failure patients with preserved ejection fraction; a pilot study.
KR20160025808A (ko) 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 피로 또는 스트레스의 예방 또는 회복용 조성물
Cao et al. Intensive versus conventional insulin therapy in nondiabetic patients receiving parenteral nutrition after D2 gastrectomy for gastric cancer: a randomized controlled trial
CN108371326B (zh) 一种降血糖的功能性组合物
WO2000062797A1 (en) Remedies for autonomic neuropathy
JP2016210720A (ja) 運動機能改善剤、呼吸機能改善剤または認知能改善剤
Børsheim et al. Plasma amino acid concentrations during late rehabilitation in patients with traumatic brain injury
US20230131476A1 (en) Compositions containing amino acids and methods of using such compositions for treating sarcopenia
RU2201179C2 (ru) Способ лечения диабетических ретинопатий
JP6749097B2 (ja) タンパク質の異化軽減または同化促進のための剤
Fraser et al. Nutrition issues following spinal cord injury
Oyama et al. Jelly-type carbohydrate supplement in healthy subjects suppresses the catabolism of adipose tissue and muscle protein and improves their satisfactions
JP2023530485A (ja) 運動なしで、筋量、筋力および筋機能を改善するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用法
Winkler et al. 19 Nutrition and the Geriatric Surgery Patient
Aryana et al. Aging and Sarcopenia
Patankar et al. Effect of balanced low calorie meal replacement formula diet in the management of overweight/obesity and metabolic profile-a retrospective clinical experience report
Aquilani et al. Clinical Study Unaffected Arm Muscle Hypercatabolism in Dysphagic Subacute Stroke Patients: The Effects of Essential Amino Acid Supplementation
CHAKRABORTY HORMONE TREATMENT” A POPULAR ANTI-AGEING THERAPY

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250208

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250208